{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:31:45Z","timestamp":1793633505684,"version":"4.5.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omtn.2026.103085","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:30:48Z","timestamp":1789680648000},"page":"103085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["2026: A watershed year for RNA therapeutics\u2014From breakthrough vaccines to chronic indications and beyond"],"prefix":"10.1016","volume":"37","author":[{"given":"Cesare","family":"Di Nitto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-3308","authenticated-orcid":false,"given":"Paloma H.","family":"Giangrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103085_bib1","article-title":"Moderna announces positive Phase 3 results for intesmeran (mRNA-4157\/V940) individualized neoantigen therapy in combination with pembrolizumab","year":"2026","journal-title":"Investor Insights"},{"key":"10.1016\/j.omtn.2026.103085_bib2","series-title":"Brii Bio Doses First Participant in Phase 1 Trial of BRII-5395, an mRNA Therapeutic Vaccine for Advanced Hepatocellular Carcinoma","year":"2026"},{"key":"10.1016\/j.omtn.2026.103085_bib3","article-title":"Navigating the evolving paradigm of RNA therapeutics: Delivery, design, and clinical horizons","volume":"35","author":"Giangrande","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103085_bib4","article-title":"Nucleoside-modified mRNA therapy restores functional defects in human Fabry disease cardiomyocytes","volume":"13","author":"Juchem","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2026.103085_bib6","first-page":"2612","article-title":"mRNA vaccines hit key late-stage clinical milestones in seasonal influenza and combination respiratory indications","volume":"632","year":"2026","journal-title":"Nature"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:17:08Z","timestamp":1793632628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2162253126002568"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103085","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2026: A watershed year for RNA therapeutics\u2014From breakthrough vaccines to chronic indications and beyond","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103085"}}